Improving influenza and adenovirus yield with the addition of insulin for vaccine production
One of the challenges in the vaccine industry is to produce large quantities of vaccines in a rapid and cost-effective way.
Major changes to current bioprocesses are difficult to implement due to costs associated with the regulatory approval process. Therefore, we propose to use insulin, a growth factor currently used and approved in several processes and production platforms, as an additive to boost cell growth, productivity and viral yield.
Click here for more information
